Transforming Care For Patients With Chronic Pain And Urology Disorders
Relevium Medical is pioneering a novel class of highly selective small-molecule ablation agents targeting TRPV1 to address painful and urological disorders rooted in peripheral nervous system hyperexcitability
ABOUT RELEVIUM MEDICAL
Innovative. Life-changing.
Relevium Medical is a biopharmaceutical company developing advanced, patient-focused therapies for chronic pain and urology disorders. A spin-out from Europe’s only Stanford BioDesign-affiliated BioInnovate Program and backed by Y Combinator and leading investors, we are driven to deliver safe, long-lasting relief where current treatments fall short. Our multidisciplinary team of scientists, chemists, and industry experts, supported by world-class clinical advisors, is advancing breakthrough solutions to improve patients’ lives.
A PIONEERING APPROACH
Pharmaceutical Excellence
Chronic pain is our therapeutic pillar - validated as an urgent clinical need by key stakeholders.
Our science is based on TRPV1-targeting therapeutics to treat pain and other conditions involving hyperexcitability of the peripheral nervous system. Our novel prodrug therapeutic was developed to overcome the burning and tolerability issues that have limited the widespread use of TRPV1 agonist drugs until now. Our therapeutics are highly tolerable, with superior efficacy compared to conventional TRPV1 agonist drugs, no systemic side effects, and without the addiction potential and side effects of opioids.
We are also advancing this pipeline to address urologic hyperexcitability disorders.
